Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia

Scandinavian Journal of Pain

Volumn 4, Issue 2, 2013, Pages 65-74

  Petzke, F ^a   Jensen, K B ^b,c   Kosek, E ^d   Choy, E ^e   Carville, S ^f   Fransson, P ^d   Williams, S C R ^g   Marcus, H ^h   Mainguy, Y ⁱ   Ingvar, M ^d   Gracely, R H ^j  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b MIT HMS MGH Athinoula A Martinos Center for Biomedical Imaging   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

ⁱ Centre d'Immunologie Pierre Fabre   (France)

^j UNIVERSITY OF NORTH CAROLINA   (United States)

more..

Author keywords

Fibromyalgia; FMRI; Milnacipran; Pharmacological MRI; Psychophysics; SNRI

Indexed keywords

MILNACIPRAN; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBROMYALGIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROIMAGING; PAIN; PAIN ASSESSMENT; PRESSURE SENSATION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84876120301     PISSN: 18778860     EISSN: 18778879     Source Type: Journal    
DOI: 10.1016/j.sjpain.2012.10.002     Document Type: Article

References (44)

1. Wolfe F., Clauw D.J., Fitzcharles M.A., Goldenberg D.L., Katz R.S., Mease P., Russell A.S., Russell I.J., Winfield J.B., Yunus M.B. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010, 62:600-610.
2. Carville S.F., Arendt-Nielsen L., Bliddal H., Blotman F., Branco J.C., Buskila D., Da Silva J.A.P., Danneskiold-Samsoe B., Dincer F., Henriksson C., Henriksson K.G., Kosek E., Longley K., McCarthy G.M., Perrot S., Puszczewicz M., Sarzi-Puttini P., Silman A., Spath M., Choy EH EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008, 67:536-541.
3. Moret C., Charveron M., Finberg J., Couzinier J.M.B. Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 1985, 24:1211-1219.
4. Vaishnavi S., Nemeroff C., Plott S., Rao S., Kranzler J., Owens M. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004, 55:320-322.
5. Nakajima K., Obata H., Iriuchijima N., Saito S. An increase in spinal cord noradrenaline is a major contributor to the antihyperalgesic effect of antidepressants after peripheral nerve injury in the rat. Pain 2012, 153:990-997.
6. Kosek E., Ekholm J., Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain 1996, 68:375-383.
7. Lautenbacher S., Rollman G.B. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 1997, 13:189-196.
8. Mountz J., Bradley L., Modell J., Alexander R., Triana-Alexander M., Aaron L., Stewart K., Alarcón G., Mountz J. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995, 38:926-938.
9. Staud R.V.C.J., Cannon R.L., Mauderli A.P., Price D.D. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 2001, 91:165-175.
10. Sörensen J., Graven-Nielsen T., Henriksson K.G., Bengtsson M., Arendt-Nielsen L. Hyperexcitability in fibromyalgia. J Rheumatol 1998, 25:152-155.
11. Gracely R.H., Petzke F., Wolf M., Clauw D. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002, 46:1333-1343.
12. Jensen K.B., Kosek E., Petzke F., Carville S., Fransson P., Marcus H., Williams S.C.R., Choy E., Giesecke T., Mainguy Y., Gracely R., Ingvar M. Evidence of dysfunctional pain inhibition in fibromyalgia reflected in rACC during provoked pain. Pain 2009, 144:95-100.
13. Jensen K.B., Loitoile R., Kosek E., Petzke F., Carville S., Fransson P., Marcus H., Williams S.C.R., Choy E., Mainguy Y., Vitton O., Gracely R., Gollub R.L., Ingvar M., Kong J. Patients with fibromyalgia display less functional connectivity in the brain's pain inhibitory network. Mol Pain 2012, 8:32-36.
14. Mainguy Y. Functional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipran. Hum Psychopharmacol: Clin Exp (Suppl) 2009, 24:19-23.
15. Wolfe F., Smythe H., Yunus M., Bennett R., Bombardier C., Goldenberg D., Tugwell P., Campbell S., Abeles M., Clark P. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172.
16. Petzke F., Clauw D.J., Ambrose K., Khine A., Gracely R.H. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. Pain 2003, 105:403-413.
17. Petrovic P., Kalso E., Petersson K.M., Ingvar M. Placebo and opioid analgesia - imaging a shared neuronal network. Science 2002, 295:1737-1740.
18. Brooks J., Tracey I. From nociception to pain perception: imaging the spinal and supraspinal pathway. J Anat 2005, 207:19-33.
19. Gracely R.H., Geisser M.E., Giesecke T., Grant M.A.B., Petzke F., Williams D.A., Clauw D.J. Pain catastrophizing and neural responses to pain among persons with Fibromyalgia. Brain 2004, 127:835-843.
20. Ingvar M. Pain and functional imaging. Philos Trans R Soc Lond B: Biol Sci 1999, 354:1347-1358.
21. Tracey I. Nociceptive processing in the human brain. Curr Opin Neurobiol 2005, 15:478-487.
22. Napadow V., LaCount L., Park K., AsSeine S., Clauw D., Harris R.E. Intrinsic brain connectivity in fibromyalgia is associated with chronic pain intensity. Arthritis Rheum 2010, 62:2545-2555.
23. Derry S., Gill D., Phillips T., Moore R.A. Milnacipran for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2012, 3:CD008244.
24. Mease P., Clauw D., Gendreau R., Rao S., Kranzler J., Chen W., Palmer R. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 2009, 36:398-409.
25. Clauw D., Mease P., Palmer R., Gendreau R., Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008, 30:1988-2004.
26. Giesecke T., Williams D.A., Harris R.E., Cupps T.R., Tian X., Tian T.X., Gracely R.H., Clauw D.J. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 2003, 48:2916-2922.
27. Julien N., Goffaux P., Arsenault P., Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 2005, 114:295-302.
28. Gracely R., Grant M., Giesecke T. Evoked pain measures in fibromyalgia. Best Pract Res Clin Rheumatol 2003, 17:593-609.
29. Legrain V., Iannetti G.D., Plaghki L., Mouraux A. The pain matrix reloaded: a salience detection system for the body. Prog Neurobiol 2011, 93:111-124.
30. Geisser M.E., Casey K.L., Brucksch C.B., Ribbens C.M., Appleton B.B., Crofford L.J. Perception of noxious and innocuous heat stimulation among healthy women and women with fibromyalgia: association with mood, somatic focus, and catastrophizing. Pain 2003, 102:243-250.
31. Hsieh J.-C., Belfrage M., Stone-Elander S., Hansson P., Ingvar M. Central representation of chronic ongoing neuropathic pain studied by positron emission tomography. Pain 1995, 63:225-236.
32. Niddam D., Chan R.-C., Lee S.-H., Yeh T.-C., Hsieh J.-C. Central modulation of pain evoked from myofascial trigger point. Clin J Pain 2007, 23:440-448.
33. Mantini D., Caulo M., Ferretti A., Romani G.L., Tartaro A. Noxious somatosensory stimulation affects the default mode of brain function: evidence from functional MR imaging. Radiology 2009, 253:797-804.
34. Zyloney C., Jensen K.B., Gollub R.L., LaViolette P., Kaptchuk T., Kong J. Imaging the functional connectivity of the Periaqueductal Gray during verum and sham electroacupuncture treatment. Mol Pain 2010, 16:80-84.
35. Fransson P., Marrelec G. The precuneus/posterior cingulate cortex plays a pivotal role in the default mode network: evidence from a partial correlation network analysis. NeuroImage 2008, 42:1178-1184.
36. Hauser W., Wolfe F., Tolle T., Uceyler N., Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 2012, 26:297-307.
37. Borsook D., Becerra L., Hargreaves R. A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov 2006, 5:411-424.
38. Honey G., Bullmore E. Human pharmacological MRI. Trends Pharmacol Sci 2004, 25:366-374.
39. Tracey I. Prospects for human pharmacological functional magnetic resonance imaging (phMRI). J Clin Pharmacol 2001, 21:8S-21S.
40. Abel K., Allin M., Kucharska-Pietura K., David A., Andrew C., Williams S., Brammer M., Phillips M. Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. Neuroreport 2003, 14:387-391.
41. Seifritz E., Bilecen D., Hanggi D., Haselhorst R., Radu E., Wetzel S., Seelig J., Scheffler K. Effect of ethanol on BOLD response to acoustic stimulation: implications for neuropharmacological fMRI. Psychiatry Res 2000, 99:1-13.
42. Bantick S.J., Wise R.G., Ploghaus A., Clare S., Smith S., Tracey I. Imaging how attention modulates pain in humans using functional MRI. Brain 2002, 125:310-319.
43. Honey G., Bullmore E., Soni W., Varatheesan M., Williams S., Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci U S A 1999, 96:13432-13437.
44. Davidson R., Irwin W., Anderle M., Kalin N. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry 2003, 160:64-75.